"Dose dense" chemotherapy in ovarian cancer

International Journal of Gynecological Cancer

Volumn 15, Issue 6 SUPPL. 3, 2005, Pages 226-232

  Vasey, Paul A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Chemotherapy; Dose density; Dose intensity; Ovarian carcinoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE DENSIFICATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE; PLATINUM COMPOUNDS; TAXOIDS;

EID: 30744467473     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00438.x     Document Type: Review

References (38)

1. Cannistra SA, Bast RC, Berek JS et al. Progress in the management of gynaecologic cancer: consensus summary statement. J Clin Oncol 2003;21(10S):129S-132S.
2. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
3. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
5. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomised phase III trial of the AGO OVAR, the NCIC_CTG and the EORTC GCG [abstract]. Proc Am Soc Clin Oncol 2004;23. Abstract 5005.
6. Skipper HE. Laboratory models: some historical perspectives. Cancer Treat Rep 1986;70:3-7.
7. Norton L, Simon R, Brereton JD et al. Predicting the course of Gompertzian growth. Nature 1976;264:542-5.
8. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-71.
9. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;3(Suppl.): 30-5.
10. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281-7.
11. Hryniuk W, Ragaz J, Peters W. Dose density by any other name [letter]. J Clin Oncol 2004;22:750.
12. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node positive primary breast cancer. First report of the intergroup trial C9741/Cancer and Leukemia Group B trial 974. J Clin Oncol 2003;21:1431-9.
13. Green MC, Buzdar AU, Smith S et al. Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic response complete remission rates when compared to every 3-week P therapy followed by FAC: final results of a prospective phase III randomized trial [abstract]. Proc Am Clin Oncol 2002;21:35a. Abstract 135.
14. Jackisch C, Von Minckwitz G, Raab G et al. Primary endpoint analysis of the Geparduo-study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential Adriamycin/docetaxel combination in operable breast cancer [abstract]. Breast Cancer Res Treat 2002;76(Suppl.):S50. Abstract 152.
15. Vasey PA, Kaye SB. Dose intensity in ovarian cancer. In: Gershenson DM, McGuire WP, eds. Ovarian cancer controversies in management. New York: Churchill Livingstone, 1997:139-69.
16. Ngan HYS, Choo YC, Cheung M et al. A randomised study of highdose versus lowdose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 1989;35:221-7.
17. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:2113-9.
18. Gordon AN, Tonda M, Sun S et al. Long term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase III randomised study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
19. National Institute for Clinical Excellence. Final appraisal determination paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line and subsequent treatment of advanced ovarian cancer (review). London, National Institute for Clinical Excellence. Issue date: March 2005.
20. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30:444-50.
21. Chang AY, Boros L, Garrow R et al. Paclitaxel by 3-hour infusion followed by 96 hour infusion on failure in patients with refractory malignant disease. Semin Oncol 1995;22(S6):124-7.
22. Seidman AD, Hochhauser D, Gollub M et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in patients with metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
23. Spriggs DR, Brady M, Rubin S et al. A phase III randomised trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected stage III or stage IV epithelial ovarian cancer (GOG162). J Clin Oncol 2004;22(14S):5004.
24. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 2003;90:S34-8.
25. Fenelly D, Aghajanian C, Shapiro F et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
26. Markman M, Hall J, Spitz D et al. Phase II study of weekly single agent paclitaxel in platinum/paclitaxel refractory ovarian cancer. J Clin Oncol 2002;20:2365-9.
27. Bolis G, Scarfone G, Luchini L et al. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin/carboplatin based regimen. Eur J Cancer 1994;30A:1764-8.
28. Rosenberg P, Andersson H, Boman K et al. Randomised trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41: 418-24.
29. Berkenblit A, Seiden MV, Matulonis UA et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer or fallopian tube cancer. Gynecol Oncol 2004; 95:624-31.
30. Bence AK, Mattingly CA, Desimone PA et al. Evaluation of topotecan cytotoxicity and topoisomerase levels in non-small cell lung cancer cells. Proc Am Assoc Cancer Res 2002;43:247.
31. Hoskins P, Eisenhauer E, Beare S et al. Randomised phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:2233-7.
32. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynaecologic Oncology Group study. J Clin Oncol 1998;16: 405-10.
33. Mabel JS. Therapeutic synergism in murine tumours for combination of cisdiamminedichloroplatinum with VP-16-213 or BCNU. Proc Am Cancer Res 1979;20:230.
34. Van der Burg M, de Wit R, van putten WL et al. Weekly cisplatin and daily etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002;86: 19-25.
35. Meyer T, Nelstrop AE, Mahmoudi M et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001;12:1705-9.
36. Bruzzone M, Mencoboni M, Mammoliti F et al. Second-line chemotherapy with gemcitabine and vepesid (VP16) in platinum resistant advanced ovarian cancer patients [abstract]. Proc Am Soc Clin Oncol 2004;23. Abstract 5082.
37. Havrilesky LJ, Alvarez AA, Sayer RA et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynaecol Oncol 2003;88:51-7.
38. Van der Burg ME, Vergote I, Burger CW et al. Phase II study of weekly paclitaxel carboplatin in the treatment of progressive ovarian cancer. J Clin Oncol 2004;22(14S):5058.